12:00 AM
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CALAA-01: Completed Phase Ib enrollment

Arrowhead Research Corp. (NASDAQ:ARWR, Pasadena, Calif.) said its Calando subsidiary completed enrollment of an undisclosed number of patients in an...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >